High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years (Q36902837)

17 August 2017

1 reference

title

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years (English)

1 reference

17 August 2017

Mehta J

1

1 reference

17 August 2017

Singhal S

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

6 August 2007

1 reference

Bone Marrow Transplantation

17 August 2017

published in

1 reference

17 August 2017

volume

40

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

1101-1114

1 reference

The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

The role of autologous transplantation in patients with multiple myeloma aged 65 years and over

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melph

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Treatment of relapsed and refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

An elective single autograft with high-dose melphalan: single-center study of 451 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Prognostic Factors in Autologous Stem Cell Transplantation for Multiple Myeloma: An EBMT Registry Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

1 reference

7 January 2021

VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Effect of complete response on outcome following autologous stem cell transplantation for myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

1 reference

7 January 2021

Lenalidomide in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705799

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705799

1 reference

17 August 2017

1 reference